Retirement Planning Co of New England Inc. Sells 200 Shares of Insulet Co. (NASDAQ:PODD)

Retirement Planning Co of New England Inc. decreased its position in shares of Insulet Co. (NASDAQ:PODD) by 7.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,592 shares of the medical instruments supplier’s stock after selling 200 shares during the quarter. Retirement Planning Co of New England Inc.’s holdings in Insulet were worth $677,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PODD. Raymond James Financial Inc. bought a new position in shares of Insulet during the 4th quarter worth $69,433,000. Alecta Tjanstepension Omsesidigt bought a new position in Insulet in the 4th quarter worth about $53,184,000. Charles Schwab Investment Management Inc. boosted its stake in Insulet by 43.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after purchasing an additional 193,839 shares during the period. Westfield Capital Management Co. LP boosted its stake in Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after purchasing an additional 163,388 shares during the period. Finally, Proficio Capital Partners LLC bought a new position in Insulet in the 4th quarter worth about $28,422,000.

Wall Street Analysts Forecast Growth

PODD has been the subject of several analyst reports. JPMorgan Chase & Co. raised their target price on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, December 12th. Canaccord Genuity Group raised their target price on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. TD Cowen raised their target price on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Stifel Nicolaus raised their target price on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. Finally, Raymond James restated an “outperform” rating and issued a $328.00 target price (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $292.06.

Insiders Place Their Bets

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.47% of the company’s stock.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $261.63 on Tuesday. The stock has a market cap of $18.37 billion, a price-to-earnings ratio of 45.19, a P/E/G ratio of 3.62 and a beta of 1.29. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The stock’s 50-day moving average is $272.40 and its 200 day moving average is $255.72.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. On average, sell-side analysts anticipate that Insulet Co. will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.